GET DAILY SIGNALSHealthcare Realty Trust (HR) Delivers Q3 Beat and Raises Full-Year Guidance
Key Takeaways
- Healthcare Realty Trust (NYSE: HR) reported normalized funds from operations (FFO, a key earnings measure for real estate investment trusts) of $0.42 per share, topping the consensus estimate of $0.41.
- Total revenue came in at $286.64 million, beating analyst expectations by roughly $3.19 million.
- Management raised its full-year 2026 normalized FFO guidance to a range of $1.65 to $1.67 per share.
- Same-store cash net operating income (NOI, income generated from property operations) grew 5.1%, supported by cash leasing spreads of 8.6%.
- GAAP (generally accepted accounting principles) net loss narrowed to $0.05 per share, down from $0.17 per share a year earlier.
- The board maintained its quarterly dividend of $0.24 per share.
- For more details on HR's major news, today's price move, price targets, and forecasts, explore the dedicated pages on Tickeron.
Why These Results Matter
Healthcare Realty Trust is the largest publicly traded, pure-play owner and operator of medical outpatient buildings in the United States, a segment that benefits as healthcare delivery shifts away from hospitals toward lower-cost outpatient settings. This quarterly report serves as an important checkpoint on the company's "Healthcare Realty 2.0" strategic plan, which focuses on portfolio optimization, stronger lease economics, and disciplined capital allocation. The third quarter of 2026 indicates whether the turnaround's operating momentum—marked by record leasing, improving occupancy, and rising same-store NOI—can persist, and whether management's guidance increases are translating into durable per-share earnings growth.
Breaking Down the Reported Figures
For the third quarter ended September 30, 2026, Healthcare Realty reported normalized FFO of $0.42 per diluted share, edging past the $0.41 consensus estimate and matching the prior-year figure of $0.41. NAREIT FFO rose to $0.38 per share from $0.34 a year ago. Total revenue of $286.64 million surpassed expectations by about $3.19 million, though it declined from $297.77 million in the prior-year quarter as ongoing property dispositions reduced the top line. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Operationally, same-store cash NOI increased 5.1%, tenant retention held at 88.0%, and average cash leasing spreads reached 8.6%. The company executed 1.5 million square feet of new and renewal leases. GAAP net loss attributable to common stockholders narrowed to $15.8 million, or $0.05 per share, a meaningful improvement from a loss of $57.7 million, or $0.17 per share, a year earlier.
Management raised 2026 normalized FFO guidance to $1.65–$1.67 per share (from $1.62–$1.66), lifted NAREIT FFO guidance to $1.48–$1.52 per share, and increased same-store cash NOI growth guidance to 5.00%–5.25% (from 4.25%–5.00%).
Market Reaction and Sentiment
Healthcare Realty shares rose more than 3% in the session following the release, reflecting investor approval of the FFO beat and the upwardly revised guidance. Sentiment around the stock has been improving through 2026 as the company's operational turnaround gains traction, with several sell-side analysts raising price targets earlier in the year. The combination of a modest earnings beat, a second consecutive guidance increase, and continued share repurchases reinforces the view that management's strategic plan is producing measurable results.
What to Watch Going Forward
Looking ahead, investors should watch whether the company can sustain its same-store NOI growth near the low-single-digit-to-mid-single-digit range while executing on its portfolio optimization. The raised full-year guidance now implies solid momentum through the fourth quarter, but execution risk remains around signed-but-not-occupied leases converting into rent-paying occupancy. Capital allocation will remain a central theme. Healthcare Realty repurchased 4.2 million shares during the quarter and early October at an average price of $17.74, and it renewed its $500 million buyback authorization. Ongoing dispositions, refinancing activity, and acquisitions within its joint venture with KKR will shape both the balance sheet and per-share earnings. Finally, investors should monitor leverage and interest-rate sensitivity. Net debt to adjusted EBITDA stood at 5.5x, and the company carries substantial near-term liquidity of roughly $1.6 billion. How management balances growth, buybacks, and debt reduction will be an important driver of future results and investor confidence.
Using AI Tools in My Research
In my work tracking healthcare real estate and other sectors, I regularly use Tickeron’s AI Screener as part of the process. It helps filter opportunities based on fundamentals, patterns, and performance metrics more efficiently than manual methods, allowing me to cross-check ideas alongside earnings analysis and identify additional data-driven names quickly.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for HR turns positive, indicating new upward trend
HR saw its Momentum Indicator move above the 0 level on October 16, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 93 similar instances where the indicator turned positive. In 58 of the 93 cases, the stock moved higher in the following days. The odds of a move higher are at 62%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where HR's RSI Oscillator exited the oversold zone, 16 of 31 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 52%.
The Moving Average Convergence Divergence (MACD) for HR just turned positive on October 13, 2026. Looking at past instances where HR's MACD turned positive, the stock continued to rise in 23 of 48 cases over the following month. The odds of a continued upward trend are 48%.
Following a +0.28% 3-day Advance, the price is estimated to grow further. Considering data from situations where HR advanced for three days, in 139 of 285 cases, the price rose further within the following month. The odds of a continued upward trend are 49%.
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The 50-day moving average for HR moved below the 200-day moving average on October 16, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 62%.
HR broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for HR entered a downward trend on October 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 9 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 24 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 43 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.425) is normal, around the industry mean (3.066). HR has a moderately low P/E Ratio (-67.423) as compared to the industry average of (27.232). Projected Growth (PEG Ratio) (0.310) is also within normal values, averaging (1.649). Dividend Yield (0.055) settles around the average of (0.048) among similar stocks. P/S Ratio (5.757) is also within normal values, averaging (6.013).
The Tickeron Price Growth Rating for this company is 59 (best 1 - 100 worst), indicating fairly steady price growth. HR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 91 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 63, placing this stock worse than average.
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a real estate investment trust
Industry PublishingBooksMagazines
Advertisement